Will the U.S. Keep Buying Medicine for ‘Black Swan’ Attacks?

An analytical chemist in Pennsylvania conducts testing for a developmental drug in 2003. Lawmakers are set to consider whether to continue funding a multibillion-dollar program to develop drug treatments for relatively unlikely unconventional attacks.
National Journal
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login